Leerink Partnrs Predicts Reduced Earnings for NeoGenomics

NeoGenomics, Inc. (NASDAQ:NEO) – Equities researchers at Leerink Partnrs dropped their Q1 2025 earnings estimates for NeoGenomics in a note issued to investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings per share of ($0.07) for the quarter, down from their prior estimate of ($0.02). The consensus estimate for NeoGenomics’ current full-year earnings is ($0.16) per share. Leerink Partnrs also issued estimates for NeoGenomics’ Q2 2025 earnings at ($0.03) EPS, Q4 2025 earnings at $0.01 EPS, FY2025 earnings at ($0.10) EPS and FY2026 earnings at $0.07 EPS.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.04. The company had revenue of $167.80 million during the quarter, compared to analysts’ expectations of $167.00 million. NeoGenomics had a negative return on equity of 2.11% and a negative net margin of 12.07%. The firm’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.06) earnings per share.

Several other equities analysts have also recently issued reports on the stock. Bank of America boosted their price objective on shares of NeoGenomics from $18.00 to $19.00 and gave the company a “neutral” rating in a research note on Friday, December 13th. Needham & Company LLC reiterated a “buy” rating and set a $19.00 price target on shares of NeoGenomics in a research note on Friday, January 10th. Jefferies Financial Group initiated coverage on shares of NeoGenomics in a report on Tuesday, December 10th. They set a “buy” rating and a $22.00 price target for the company. Finally, Benchmark lowered NeoGenomics from a “buy” rating to a “hold” rating in a report on Monday, January 13th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.30.

NeoGenomics Price Performance

Shares of NASDAQ:NEO opened at $14.66 on Thursday. NeoGenomics has a one year low of $12.13 and a one year high of $19.11. The stock has a market capitalization of $1.88 billion, a price-to-earnings ratio of -24.03 and a beta of 1.24. The company has a 50-day simple moving average of $16.56 and a 200-day simple moving average of $15.68. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.91 and a current ratio of 1.99.

Insider Buying and Selling

In other NeoGenomics news, General Counsel Alicia C. Olivo sold 5,175 shares of NeoGenomics stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $15.36, for a total value of $79,488.00. Following the completion of the sale, the general counsel now owns 37,129 shares in the company, valued at $570,301.44. The trade was a 12.23 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in NEO. Fernwood Investment Management LLC grew its stake in NeoGenomics by 1.0% during the third quarter. Fernwood Investment Management LLC now owns 89,500 shares of the medical research company’s stock worth $1,320,000 after buying an additional 900 shares during the period. FMR LLC lifted its holdings in shares of NeoGenomics by 7.6% during the 3rd quarter. FMR LLC now owns 13,255 shares of the medical research company’s stock valued at $196,000 after acquiring an additional 931 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of NeoGenomics by 42.3% during the 3rd quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 987 shares in the last quarter. KBC Group NV boosted its position in NeoGenomics by 33.1% during the 3rd quarter. KBC Group NV now owns 4,530 shares of the medical research company’s stock worth $67,000 after purchasing an additional 1,127 shares during the period. Finally, Versant Capital Management Inc increased its holdings in NeoGenomics by 174.9% in the 4th quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 1,142 shares in the last quarter. 98.50% of the stock is owned by hedge funds and other institutional investors.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.